All comparisons

Educational Wellness Information Only

This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.

Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.

Fat loss comparison

AOD-9604 vs Liraglutide

An educational, source-based comparison of AOD-9604 and Liraglutide — how each peptide works, what it's researched for, and what to know before going deeper.

Metabolic · Lipolysis
AOD-9604

Modified GH fragment researched for adipose tissue effects.

Mechanism

A modified 16-amino-acid fragment (177–191) of human growth hormone, engineered to retain the lipolytic activity of GH without its growth or insulin-resistance effects. Research suggests it stimulates lipolysis and inhibits lipogenesis.

Research areas
  • Obesity (clinical trials did not meet endpoints)
  • Osteoarthritis / cartilage repair (current research direction)
  • Localized adipose research
Considerations
  • Not FDA-approved as a therapeutic.
  • Has GRAS status in some food contexts (Australia), not equivalent to drug approval.
Full AOD-9604 profile →
Metabolic · Incretin
Liraglutide

FDA-approved daily GLP-1 receptor agonist.

Mechanism

A daily GLP-1 receptor agonist with a fatty-acid side chain that enables albumin binding and ~13-hour half-life. Mechanism mirrors semaglutide at shorter duration: enhanced glucose-dependent insulin release, slowed gastric emptying, and central appetite suppression.

Research areas
  • Type 2 diabetes (Victoza)
  • Chronic weight management (Saxenda)
  • Cardiovascular risk reduction in T2D
Considerations
  • FDA-approved; requires prescription and physician oversight.
  • GI side effects, pancreatitis risk, gallbladder events.
Full Liraglutide profile →

AOD-9604 vs Liraglutide — Key differences

  • Class: AOD-9604 is classified as Metabolic · Lipolysis, while Liraglutide is Metabolic · Incretin.
  • Primary research focus: AOD-9604obesity (clinical trials did not meet endpoints); Liraglutidetype 2 diabetes (victoza).
  • Tag: Fat loss vs Weight loss · Diabetes.

Related comparisons